The FDA warns drugmaker over opioid promotion; Watson may not be living up to the hype; Merck acquires immuno-oncology biotech
In the wake of MD Anderson's costly failure with IBM's Watson supercomputer, a Watson backlash brewing in biopharma may lead to a moment of reckoning in life sciences.
A high-profile cancer track commands attention, while wearables and IBM Watson Health come under fire.
Audit says MD Anderson Cancer Center mismanaged Watson partnership; Icahn takes stake in BMS; Sarepta sells priority review voucher to Gilead
The internet strongly agrees there's an artificial intelligence revolution going on, and it's come to pharma marketing.
Regeneron and Pfizer CEOs argue about the industry's reputation; Mylan CEO defends the EpiPen; Pfizer and IBM to partner on cancer immunotherapies
With a lead role in IBM Watson's bold gambit to transform healthcare, Kathy McGroddy-Goetz ranks as one of the enterprise's most important individuals.
Soon, IBM says, Watson will be used by one particular pharma company to create a website where, once a drug is prescribed, patients can ask questions in their own words and the website will provide answers in near real-time.